CARBON DIOXIDE, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. First approved in 2025.
Drug data last refreshed 47m ago · AI intelligence enriched 5d ago
CARBON DIOXIDE, USP is an inhaled gas product approved as an X-ray contrast agent for diagnostic imaging procedures. It functions through contrast activity mechanisms to enhance radiographic visualization. The product targets patients requiring enhanced imaging clarity during diagnostic X-ray examinations.
Recent 2025 launch signals early-stage commercial build-out with limited team infrastructure currently in place.
X-Ray Contrast Activity
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Carbon Dioxide Investigation
Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
Worked on CARBON DIOXIDE, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Only 1 linked job posting exists for this product, with roles concentrated in operational/utility functions rather than traditional pharma commercial or medical roles. This suggests a highly specialized product with minimal career development breadth at launch.
1 open roles linked to this drug